BCRX vs SRPT
BCRX: BioCryst Pharmaceuticals is a biotech company focused on commercializing and developing innovative therapies for hereditary angioedema and other rare diseases using structure-guided drug design. SRPT: A biopharmaceutical leader in genetic medicine, specializing in innovative RNA-targeted therapies and gene treatments for Duchenne muscular dystrophy and rare genetic disorders.
Side-by-side fundamentals
| Metric | BCRX | SRPT | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $9.58 | $15.89 | |
| Market cap as of 2026-07-31 | $2.4B | $1.7B | |
| P/E as of 2026-07-31 | 8.92 | 24.89 | BCRX lower |
| PEG as of 2026-07-31 | -0.01 | -23.53 | SRPT lower |
| Net margin as of 2026-07-31 | -51.7% | +3.0% | SRPT higher |
| Gross margin as of 2026-07-31 | +97.8% | +70.5% | BCRX higher |
| Operating margin as of 2026-07-31 | -45.1% | -1.1% | SRPT higher |
| ROE as of 2026-07-31 | -328.8% | +4.9% | SRPT higher |
| ROA as of 2026-07-31 | -97.3% | +1.9% | SRPT higher |
| Debt / equity as of 2026-07-31 | 2.26 | 0.56 | SRPT lower |
| Revenue growth (YoY) as of 2026-07-31 | +75.9% | -2.2% | BCRX higher |
| Revenue CAGR (3y) SEC XBRL | +22.8% | +33.1% | SRPT higher |
| Beta as of 2026-07-31 | 0.57 | 0.22 | |
| 1-year return as of 2026-07-27 close | +12.0% | +33.2% | SRPT higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.